Literature DB >> 28149866

Are we ready to introduce T790M plasma analysis in the follow up of patients with NSCLC under treatment with EGFR-TKI?

Estibaliz Alegre1, Débora Martínez2, Mónica Macías2, Álvaro González1.   

Abstract

Entities:  

Year:  2016        PMID： 28149866      PMCID： PMC5233480          DOI： 10.21037/atm.2016.11.70

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.

Authors:  E Alegre; J P Fusco; P Restituto; D Salas-Benito; M E Rodríguez-Ruiz; M P Andueza; M J Pajares; A Patiño-García; R Pio; M D Lozano; A Gúrpide; J M Lopez-Picazo; I Gil-Bazo; J L Perez-Gracia; A Gonzalez
Journal:  Tumour Biol       Date:  2016-07-29

2.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Authors:  Matthew J Niederst; Haichuan Hu; Hillary E Mulvey; Elizabeth L Lockerman; Angel R Garcia; Zofia Piotrowska; Lecia V Sequist; Jeffrey A Engelman
Journal:  Clin Cancer Res       Date:  2015-05-11       Impact factor: 12.531

3.  Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.

Authors:  Masaru Watanabe; Tomoya Kawaguchi; Shun-ichi Isa; Masahiko Ando; Akihiro Tamiya; Akihito Kubo; Hideo Saka; Sadanori Takeo; Hirofumi Adachi; Tsutomu Tagawa; Seiichi Kakegawa; Motohiro Yamashita; Kazuhiko Kataoka; Yukito Ichinose; Yukiyasu Takeuchi; Kazuhiro Sakamoto; Akihide Matsumura; Yasuhiro Koh
Journal:  Clin Cancer Res       Date:  2015-04-16       Impact factor: 12.531

Review 4.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Authors:  Erin L Stewart; Samuel Zhixing Tan; Geoffrey Liu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2015-02

Review 5.  Epidermal growth factor receptor mutations in lung adenocarcinoma.

Authors:  Markus D Siegelin; Alain C Borczuk
Journal:  Lab Invest       Date:  2013-12-30       Impact factor: 5.662

6.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

7.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

8.  EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Authors:  Kenneth S Thress; Roz Brant; T Hedley Carr; Simon Dearden; Suzanne Jenkins; Helen Brown; Tracey Hammett; Mireille Cantarini; J Carl Barrett
Journal:  Lung Cancer       Date:  2015-10-09       Impact factor: 5.705

9.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

Review 10.  Osimertinib making a breakthrough in lung cancer targeted therapy.

Authors:  Haijun Zhang
Journal:  Onco Targets Ther       Date:  2016-09-06       Impact factor: 4.147
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.